anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
In this multi-center, retrospective cohort study, we included patients who underwent IVF-ET/ICSI-ET/FET due to infertility in the department of Reproductive Medicine from 2022-11-23 to 2023-01-07. Patients who were infected with Coronavirus were observation groups; the infection status and clinical outcome were tracked. Patients who were not infected with Coronavirus were control groups. We compared different parameters between two groups. The primary outcome was ongoing pregnancy rate. Basic information about patients' menstruation, sexual desire, and sexual function were collected from Medical record system. Other information about patients' vaccination status, symptoms related to viral infection were collected by telephone follow ups. Susceptibility indicators to COVID-19 infection including fasting blood glucose, insulin, blood lipids, alpha-function, renin-angiotensinase, I-aldosterone were obtained . Reproductive function indices AMH, INHB, sex hormones, follicle retrieval rate, Gn days, total Gn, endometrial thickness, the incidence of OHSS, semen quality, oocyte maturation rate, fertilization rate, qualified embryo rate, blastocyst formation rate, and other laboratory indices of both men and women were also collected . Assisted pregnancy outcome: clinical pregnancy rate, embryo implantation rate, early abortion rate, ongoing pregnancy rate, and other clinical indicators were analyzed to determine whether there is deference in clinical outcomes between two groups.
Objective: This study aims to compare the antiviral treatment similarities and differences in the population covered by the 2024 version of the World Health Organization's (WHO) hepatitis B prevention and treatment guidelines and the current Chinese hepatitis B prevention and treatment guidelines, so as to explore their impact on the indications for antiviral therapy in Chinese patients with chronic hepatitis B (CHB). Methods: The information of patients with chronic hepatitis B virus infection who did not receive antiviral treatment was collected through the registration database of the China Clinical Research Platform for Hepatitis B Elimination. Descriptive statistics were conducted on the demographic, blood, biochemical, and virological levels of patients according to the treatment recommendations of the two versions of the guidelines. The Mann-Whitney U test and χ2 test were used to compare the differences and proportional distribution of the treatment populations covered by the two guidelines. The χ2 test was used to analyze the coverage rate of different antiviral treatment indications. Results: A total of 21,134 CHB patients without antiviral treatment were enrolled. 69.4% of patients met the 2024 versions of the WHO guidelines' recommendations. 85.0% of patients met the current Chinese hepatitis B prevention and treatment guidelines. The WHO guidelines for antiviral therapy indications were met in younger patients with higher levels of ALT, AST, and APRI scores, as well as greater proportion of patients with higher viral loads (P<0.001). The WHO guidelines recommended a cut-off value of APRI>0.5, which raised the proportion of patients on antiviral therapy from 6.6% to 30.9%. 45.7% of patients met the antiviral indications for HBV DNA >2000 IU/ml with abnormal transaminase (ALT>30 U/L for males and ALT>19 U/L for females). The reduced APRI diagnostic cut-off value and ALT treatment threshold had further increased the treatment coverage rate by 91.6% in patients with chronic HBV infection in line with the 2024 versions of WHO guidelines. Conclusion: The reduction of the APRI diagnostic cut-off value and the ALT treatment threshold, based on the current hepatitis B guidelines of China, will further improve the treatment coverage of CHB patients.
This invention concerns the molecular cloning and characterization of nucleic acids encoding molecules, referred to as relaxin-related factors, that are related to the hormone relaxin and to the insulin family of ligands. More specifically, this invention provides an isolated nucleic acid molecule encoding relaxin-related factor-1. The invention also provides an isolated nucleic acid molecule encoding relaxin-related factor-2. The present invention also provides a nucleotide sequence that encodes a relaxin-related factor, as well as cells which are genetically engineered to produce the relaxin-related factor. The invention further provides for an isolated relaxin-related factor substantially free of other proteins, as well as for an antibody which specifically binds the relaxin-related factor. The invention also provides for pharmaceutical compositions comprising a relaxin-related factor, or an antibody which specifically binds the relaxin-related factor, and a pharmaceutically acceptable carrier, as well as for methods of treatment of a human or animal body. The invention further provides for a relaxin-related factor ligandbody which comprises a relaxin-related factor fused to an immunoglobulin constant region. The invention further provides for a method of treatment comprising administering a relaxin-related factor ligandbody to a human or animal body.
###  Absorption

A three way crossover study in 25 fasting healthy subjects was conducted to compare the bioavailability of the B12 nasal spray to the B12 nasal gel and to evaluate the relative bioavailability of the nasal formulations as compared to the intramuscular injection. The peak concentrations after administration of intranasal spray were reached in 1.25 +/- 1.9 hours. The average peak concentration of B12 obtained after baseline correction following administration of intranasal spray was 757.96 +/- 532.17 pg/mL. The bioavailability of the nasal spray relative to the intramuscular injection was found to be 6.1%. The bioavailability of the B12 nasal spray was found to be 10% less than the B12 nasal gel. The 90% confidence intervals for the loge-transformed AUC(0-t) and Cmax was 71.71% - 114.19% and 71.6% - 118.66% respectively.

In pernicious anemia patients, once weekly intranasal dosing with 500 mcg B12 gel resulted in a consistent increase in pre-dose serum B12 levels during one month of treatment (p < 0.003) above that seen one month after 100 mcg intramuscular dose (Figure).

###  Distribution

In the blood, B12 is bound to transcobalamin II, a specific B-globulin carrier protein, and is distributed and stored primarily in the liver and bone marrow.

###  Elimination

About 3-8 mcg of B12 is secreted into the GI tract daily via the bile; in normal subjects with sufficient intrinsic factor, all but about 1 mcg is reabsorbed. When B12 is administered in doses which saturate the binding capacity of plasma proteins and the liver, the unbound B12 is rapidly eliminated in the urine. Retention of B12 in the body is dose-dependent. About 80-90% of an intramuscular dose up to 50 mcg is retained in the body; this percentage drops to 55% for a 100 mcg dose, and decreases to 15% when a 1000 mcg dose is given.

Figure. Vitamin B12 Serum Trough Levels After Intramuscular Solution (IM) of 100 mcg and Nasal Gel (IN) Administration of 500 mcg Cyanocobalamin After Weekly Doses.
PURPOSE: An antibacterial peptide is provided to have shorter AMP than conventional de novo design AMP. CONSTITUTION: A peptide has an amino acid sequence of sequence numbers 1-7. A pharmaceutical composition for antibacterial contains the peptide as an active ingredient. The peptide has an amino acid sequence of sequence number 4, 5, 6, or 7. A microorganism is gram positive bacteria or gram negative bacteria. The gram positive bacteria are Bacillus subtilis, Staphylococcus aureus, Staphylococcus epidermis or Micrococcus luteus. The gram negative bacteria is Escherichia coli, Shigella dysentariae, Salmonella typhimorium, Klebsiella pneumoniae, or Pseudomonas aeruginosa.
The invention discloses a fructan-rich diet replenisher and a preparation method thereof. The preparation method comprises the following steps: (1) inoculating Leuconostoc citreum fermentative bacterium in a tomato juice sucrose culture medium, and carrying out fermentation culture to obtain a fermentation liquid; and (2) centrifuging the obtained fermentation liquid, taking the supernatant, regulating the pH value, and carrying out freeze-drying. The fructan-rich diet replenisher has the advantages of wide sources and low cost. The fermentative bacterium strain Leuconostoc citreum is detected for the first time, has the fructan producing function, and is a single strain. The combination is beneficial to standardization of product quality, cost control on industrial large-scale production and protection on food safety. The fructan-rich diet replenisher breaks out the actual state of shortage in the diet replenishers using fructan as the functional component in the existing market, and thus, has very wide application prospects.
Process for the manufacture of benzodiacepine, formula (I), where r is a lower alkyl group; x is hydrogen or halogen; z is chlorine, bromo or a group of formula (II), and is a group of formula (III) or (IV). A compound of formula (V) is subjected to oxidizing substitution in glacial acetic acid, in the presence of lead tetraacetate and iodine or potassium yodide. The resultant compound is hydrolyzed in a non-aqueous mixture of cycloromethane and methanol, in the presence of an alkaline alcoxy as sodium method. The final product is purifyed by crystallization. They are used as sedatives, anticonvulsives and relaxators of the musculature. (Machine-translation by Google Translate, not legally binding)
OBJECTIVES: Intraductal papillary mucinous neoplasm (IPMN) in individuals with at least one first-degree relative with IPMN is defined as familial IPMN. However, few studies have reported on familial IPMN, its clinical characteristics, or the associated genetic factors.
MATERIALS AND METHODS: We report the case of a 58-year-old woman with multifocal IPMN and a mural nodule in the pancreatic body. The patient underwent a distal pancreatectomy and developed pancreatic head cancer 1 year and 6 months postoperatively. The patient had a family history of multifocal IPMN in her father. Therefore, a genetic predisposition to IPMN and pancreatic cancer was suspected. The patient was analyzed for germline variants, and the resected IPMN was subjected to immunohistochemical and somatic variant analyses.
RESULTS: Next-generation sequencing revealed a heterozygous germline missense variant in exon 5 of MSH6 (c.3197A>G; Tyr1066Cys). The pathogenicity of this variant of uncertain significance was suspected based on multiple in silico analyses, and the same MSH6 variant was identified in the patient's father's colonic adenoma. The mural nodule in the pancreatic body was pathologically diagnosed as a high-grade IPMN with ossification and somatic KRAS and PIK3CA variants.
CONCLUSIONS: This case revealed a possible genetic factor for familial IPMN development and presented interesting clinicopathological findings.
Eligible patients will receive short course radiation therapy (scRT) of 25Gy over 5 days (fractions) for their localized rectal cancer. Research bloods stool and tissue will be collected at three time points: Baseline, end of radiation therapy and at surgery.
The telerehabilitation group (n=104) will participate in the FP-AF program for 16 weeks. The program is administered by the AF clinics and the healthcare centers (HC) in Viborg, Skive and Silkeborg Municipalities. After enrollment, the patients will have an individual meeting with the project nurse. Here the patient (and relatives, if necessary) will be instructed in the use of the technologies and an individual plan will be formulated for the AF patient's telerehabilitation. After participation in 16 weeks the patients start a 12 weeks follow-up period, where they will only measure steps and have access to the Heartportal on their own devices.
Chronic lymphocytic leukemia (CLL) cells extensively interact with and depend on their surrounding tumor microenvironment (TME). The TME encompasses a heterogeneous array of cell types, soluble signals, and extracellular vesicles, which contribute significantly to CLL pathogenesis. CLL cells and the TME cooperatively generate a chronic inflammatory milieu, which reciprocally reprograms the TME and activates a signaling network within CLL cells, promoting their survival and proliferation. Additionally, the inflammatory milieu exerts chemotactic effects, attracting CLL cells and other immune cells to the lymphoid tissues. The intricate CLL-TME interactions also facilitate immune evasion and compromise leukemic cell surveillance. We also review recent advances that have shed light on additional aspects that are substantially influenced by the CLL-TME interplay.
Background: Heart failure (HF) is a leading cause of hospitalizations in Haiti. However, few patients return for outpatient care. The factors contributing to chronic HF care access are poorly understood. Objective: The purpose of this study is to investigate the facilitators and barriers to accessing care for chronic HF from the patients' perspectives. Methods: We conducted a qualitative descriptive study of 13 patients with HF participating in three group interviews and one individual interview. We recruited patients after discharge from a nongovernmental organization-supported academic hospital in rural Haiti. We employed thematic analysis using emergent coding and categorized themes using the socioecological model. Findings: Facilitators of chronic care included participants' knowledge about the importance of treatment for HF and engagement with health systems to manage symptoms. Social support networks helped participants access clinics. Participants reported low cost of care at this subsidized hospital, good medication accessibility, and trust in the healthcare system. Participants expressedstrong spiritual beliefs, with the view that the healthcare system is an extension of God's influence. Barriers to chronic care included misconceptions about the importance of adherence to medications when symptoms improve and remembering follow-up appointments. Unexpectedly, participants believed they should take their HF medications with food and that food insecurity resulted in missed doses. Lack of social support networks limited clinic access. The nonhealthcare costs associated with clinic visits were prohibitive for many participants. Participants expressed low satisfaction regarding the clinic experience. A barrier to healthcare was the belief that heart disease caused by mystical and supernatural spirits is incurable. Conclusions: We identified several facilitators and barriers to chronic HF care with meaningful implications for HF management in rural Haiti. Future interventions to improve chronic HF care should emphasize addressing misconceptions about HF management and fostering patient support systems for visit and medication adherence. Leveraging local spiritual beliefs may also promote care engagement.
The invention provides bismuth-containing solid dispersion granules for treating peptic ulcer. The bismuth-containing solid dispersion granules are prepared from 1 part by weight of solid dispersion and 1-3 parts by weight of filler. The solid dispersion is prepared from crude drug powder and polyethylene glycol-6000 according to the ratio of (1-2):(3-5) w/w. The crude drug powder is prepared by smashing crude drug powder including, by weight, 0.2-0.4 part of bismuth potassium citrate, 1-3 parts of girald daphne bark, 7-13 parts of bighead atractylodes rhizomes, 2-3 parts of lucid ganoderma, 5-10 parts of radix codonopsis, 5-10 parts of radix pseudostellariae, 5-10 parts of capillary wormwood herb, 5-10 parts of dandelions, 3-7 parts of radix platycodi, 3-7 parts of cablin potchouli herb and 2-4 parts of netmeg to be 200-500 mesh. The crude drug powder is prepared into the solid dispersion, the bioavailability of medicine is improved, and the anti-ulcer activity is obviously improved. However, the solid dispersion is too large in specific area, prone to moisture absorption, not suitable for storage and production, poor in fluidity and inconvenient to produce and package. In view of the situation, the granules are prepared, storage, transport and packaging of products are convenient, and meanwhile patients can conveniently take the granules.
FIELD: medicine.SUBSTANCE: invention refers to medicine, namely to thoracic surgery, and can be used in treating bronchial fistulas. For this purpose, postoperative period after detecting by method of fibrobronchoscopy of bronchial fistula with size of more than 5 mm, dermal allofybroblasts are thawed and resuspended in 2 ml of 0.9 % physiological NaCl solution to final cell concentration 2.0×10in a dose. Simultaneously, a temperature lysis of thrombocyte-enriched autologous plasma with the initial thrombocyte content of 1.85×10/l is performed to obtain 2 ml of autologous thrombocyte lysate. Obtained components are then mixed in a syringe. Syringe is connected to an endoscopic injector and 4–6 injections are made along the fistula perimeter in the submucosal layer, 1–2 mm from the edge of the fistula at distance of 1 mm at the same distance from each other. Procedure is repeated on 3rd and 5th days of treatment followed by cytological and histological control of the treatment results.EFFECT: method provides eliminating postoperative defects of bronchi with size more than 5 mm due to early initiation of therapy with activated dermal all of fibroblasts.1 cl, 5 dwg, 2 ex
Acetabular fractures were very common in high-energy injury, because of the anatomic of acetabular was in deep location and the complex form cause the diagnosis and treatment was difficult. For most of displaced acetabular fractures, the preferred treatment is open reduction and internal fixation. The purpose of surgery is to restore acetabular integrity and stability, allow early exercise, decrease complication. Acetabular posterior wall fractures were the most common, the current clinical application fixation of acetabular fractures were common plate and reconstruction steel plate. But when the acetabular posterior wall was fracture, some patients were not satisfied after surgery. The reason is mainly because the reconstruction plate need remoulding in surgery, and it not only led to the extension of operation time, but also cause poor attach. Otherwise, the reconstruction plate need location the angle of screw in surgery. If the operator lack of experience will make into the harm surrounding vessels and nerves. Some research has achieved the improvement from the anatomy of acetabular fractures in the locking plate. But there is not any plate match with the anatomy of the acetabular posterior wall.

This anatomical bone plate was designed base on before plate and had patent protection which is used in clinical trial. It was a new type of internal fixation of acetabular posterior wall fracture, this plate improve the shortcomings of existing technology, provides a pre-formed anatomical fixation plate , the direction of the locking screw holes. This design provide a better attach of acetabular posterior wall, more safe use the screw, making more stable and reliable fixation. This fixation plate was not only suitable for an experienced doctor, but also suitable for a less experienced doctors in theory. They can quickly and accurately fixed in its correct position, thus this fixation plate have advantages of improve surgical success rates, shorter hospital stay, reduce disease painful and it can used in all adult patients.
INTRODUCTION: Robot-assisted radical prostatectomy (RARP) has become a popular surgical approach for localized prostate cancer due to its favorable oncological and functional outcomes, as well as lower morbidity. In cases of intermediate- and high-risk prostate cancer, bilateral pelvic lymphadenectomy (PLND) is recommended as an adjunct to RARP (1-3). Despite its benefits, PLND can lead to surgical complications, with postoperative lymphocele formation being the most common. Most postoperative lymphoceles are clinically insignificant with variable incidence, reaching up to 60% of cases 4. However, a small percentage of patients 2-8% may experience symptomatic lymphoceles (SL), which can cause significant morbidity (4, 5).
SURGICAL TECHNIQUE: We perform our RARP technique with our standard approach in all patients (6). After vesicourethral anastomosis a modified PF created to prevent symptomatic lymphocele. We start by suturing the peritoneal fold on the right side, medially to the vas deferens, followed by a similar stitch on the left side to approximate the edges in the midline. A running suture bunches the bladder peritoneum from both sides, passing through the pubic bone periosteum to secure it in place (7). This approach keeps the lateral pelvic gutters open for lymphatic drainage, while allowing fluid drainage from the true pelvis into the abdomen. A pelvic ultrasound was done for all patients at 6 weeks post operative, and additional clinical follow-up was carried out at 3 months following surgery.
CONSIDERATIONS: We have demonstrated a modified technique of peritoneal flap (PBFB) with an initial decrease in postoperative symptomatic lymphoceles, the technique is feasible, safe, does not add significant morbidity, and does not require a learning curve.
UNLABELLED: BACKGROUND AND OBJECTIVES: Children with tracheostomies are at increased risk of tracheostomy-related complications and require extra care. Standardized training programs for caregivers can improve tracheostomy care and reduce complications. In this study, we compared caregiver knowledge and skill scores after a standardized theoretical and practical training program on tracheostomy care (IStanbul PAediatric Tracheostomy (ISPAT) project) immediately and 1 year post-training and evaluated how this training affected the children's clinical outcomes.
MATERIALS AND METHODS: We included 32 caregivers (31 children) who had received standardized training a year ago and administered the same theoretical and practical tests 1 year after training completion. We recorded tracheostomy-related complications and the number and reasons for admission to the healthcare centers. All data just before the training and 1 year after training completion were compared.
RESULTS: After 1 year of training completion, the median number of correct answers on the theoretical test increased to 16.5 from 12 at pretest (p < 0.001). Compared with pretest, at 1-year post-training practical skills assessment scores, including cannula exchange and aspiration, were significantly higher (both p < 0.001) and mucus plug, bleeding, and stoma infection reduced significantly (p = 0.002, 0.022, and 0.004, respectively). Hands-on-training scores were better than pretest but declined slightly at 1 year compared to testing immediately after training. Emergency admission decreased from 64.5% to 32.3% (p = 0.013). Hospitalization decreased from 61.3% to 35.5% (p = 0.039).
CONCLUSION: Our findings indicate that caregiver training can lead to a persistent increase in knowledge and skill for as long as 1 year, as well as improvements in several measurable outcomes, although a slight decrease in scores warrants annual repetitions of the training program.
FIELD: diabetes. SUBSTANCE: drug is characterized by a definite composition and quantitative characteristics of cell suspension prepared from native or cryopreserved hemopoietic cells of human fetal liver and/or spleen. Diabetes mellitus is treated by injecting a drug selected from preliminarily formed tissue bank of different samples taking into account individual features of patient. For reuse, preparation of the same sample is selected. EFFECT: strengthened immunocorrection mechanism in diabetes treatment. 6 cl, 12 tbl, 7 ex
This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.